Glen Eagle Advisors’s ResMed RMD Stock Holding History

Glen Eagle Advisors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5	Closed	-$1.09K	–	1067
2023 Q2	$1.09K	Hold	5	–	–	﹤0.01%	951
2023 Q1	$1.09K	Hold	5	–	–	﹤0.01%	945
2022 Q4	$1.04K	Hold	5	–	–	﹤0.01%	1012
2022 Q3	$1.09K	Hold	5	–	–	﹤0.01%	963
2022 Q2	$1.05K	Hold	5	–	–	﹤0.01%	898
2022 Q1	$1.21K	Hold	5	–	–	﹤0.01%	858
2021 Q4	$1.3K	Hold	5	–	–	﹤0.01%	848
2021 Q3	$1.32K	Buy	+5	New	+$1.37K	﹤0.01%	972
2020 Q2	–	Sell	-2	Closed	-$295	–	932
2020 Q1	$295	Hold	2	–	–	﹤0.01%	809
2019 Q4	$310	Hold	2	–	–	﹤0.01%	878
2019 Q3	$270	Hold	2	–	–	﹤0.01%	803
2019 Q2	$244	Buy	+2	New	+$222	﹤0.01%	780

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Glen Eagle Advisors's RMD Position: Q3 2023 in Review

Glen Eagle Advisors sold out of ResMed (RMD) in Q3 2023, closing a stake of 5 shares — an estimated $1.09K sold.

Glen Eagle Advisors first reported a position in RMD in Q2 2019 and held it in 12 quarters. The position peaked at $1.32K in Q3 2021. 657 funds tracked by Wall St. Rank hold RMD as of Q3 2023.

Glen Eagle Advisors reported no remaining ResMed position as of Q3 2023 after selling out during the quarter.
Glen Eagle Advisors sold 5 ResMed shares in Q3 2023, an estimated $1.09K.
Glen Eagle Advisors first reported a position in ResMed in Q2 2019 and held it in 12 quarters.
Glen Eagle Advisors's ResMed position peaked at $1.32K in Q3 2021.
657 funds tracked by Wall St. Rank held ResMed as of Q3 2023.

Based on Glen Eagle Advisors's 13F filing for Q3 2023, filed 13 Aug 2024.